Clinical Trials
14 trialsNCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT05741294 2025-02-20
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Almirall, S.A.
Phase 4 Completed
NCT03327831 2024-06-27
Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
University of California, Irvine
Phase 4 Completed
NCT02866695 2022-03-09
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
University of California, San Francisco
Phase 4 Completed
NCT01000636 2021-05-26
Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
Galderma R&D
Phase 4 Completed
NCT03511326 2021-02-18
SESAME 2
Galderma R&D
Phase 4 Completed
NCT02446223 2019-09-06
Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%
Goldman, Butterwick, Fitzpatrick and Groff
Phase 4 Completed
NCT00695578 2018-12-31
Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy
Wake Forest University Health Sciences
Phase 4 Completed
NCT00696488 2018-09-10
Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population
Wake Forest University Health Sciences
Phase 4 Completed
NCT02716714 2018-04-18
Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis
Korea University
Phase 4 Completed
NCT02251652 2017-04-26
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
Icahn School of Medicine at Mount Sinai
Phase 4 Completed
NCT00774787 2016-11-07
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Rigel Dermatology
Phase 4 Completed
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated
NCT00116649 2010-07-20
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Graceway Pharmaceuticals, LLC
Phase 4 Completed